Swine Vaccines Market (By Type: Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo, Actinobacillus Pleuropneumonia, PRRS, Foot & Mouth Disease, Pseudorabies, PEDV; By Product: Attenuated Live Vaccines, Inactivated Vaccines, Subunit Vaccines, DNA Vaccines, Recombinant Vaccines) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 20212030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Swine Vaccines Market, By Type

7.1.  Swine Vaccines Market, by Type, 2021-2030

7.1.1.    Swine Influenza

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Classical Swine Fever

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Porcine Parvovirus

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    Porcine Circovirus Type 2

7.1.4.1.        Market Revenue and Forecast (2017-2030)

7.1.5.    M.Hyo

7.1.5.1.        Market Revenue and Forecast (2017-2030)

7.1.6.    ActinobacillusPleuropneumonia

7.1.6.1.        Market Revenue and Forecast (2017-2030)

7.1.7.    PRRS

7.1.7.1.        Market Revenue and Forecast (2017-2030)

7.1.8.    Foot & Mouth Disease

7.1.8.1.        Market Revenue and Forecast (2017-2030)

7.1.9.    Pseudorabies

7.1.9.1.        Market Revenue and Forecast (2017-2030)

7.1.10.  PEDV

7.1.10.1.      Market Revenue and Forecast (2017-2030)  

Chapter 8.  Global Swine Vaccines Market, By Product

8.1.  Swine Vaccines Market, by Product, 2021-2030

8.1.1.    Attenuated Live Vaccines

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Inactivated Vaccines

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Subunit Vaccines

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    DNA Vaccines

8.1.4.1.        Market Revenue and Forecast (2017-2030)

8.1.5.    Recombinant Vaccines

8.1.5.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Swine Vaccines Market, Regional Estimates and Trend Forecast

9.1.  North America

9.1.1.    Market Revenue and Forecast, by Type (2017-2030)

9.1.2.    Market Revenue and Forecast, by Product (2017-2030)

9.1.3.    U.S.

9.1.3.1.        Market Revenue and Forecast, by Type (2017-2030)

9.1.3.2.        Market Revenue and Forecast, by Product (2017-2030)

9.1.4.    Rest of North America

9.1.4.1.        Market Revenue and Forecast, by Type (2017-2030)

9.1.4.2.        Market Revenue and Forecast, by Product (2017-2030)

9.2.  Europe

9.2.1.    Market Revenue and Forecast, by Type (2017-2030)

9.2.2.    Market Revenue and Forecast, by Product (2017-2030)

9.2.3.    UK

9.2.3.1.        Market Revenue and Forecast, by Type (2017-2030)

9.2.3.2.        Market Revenue and Forecast, by Product (2017-2030)

9.2.4.    Germany

9.2.4.1.        Market Revenue and Forecast, by Type (2017-2030)

9.2.4.2.        Market Revenue and Forecast, by Product (2017-2030)

9.2.5.    France

9.2.5.1.        Market Revenue and Forecast, by Type (2017-2030)

9.2.5.2.        Market Revenue and Forecast, by Product (2017-2030)

9.2.6.    Rest of Europe

9.2.6.1.        Market Revenue and Forecast, by Type (2017-2030)

9.2.6.2.        Market Revenue and Forecast, by Product (2017-2030)

9.3.  APAC

9.3.1.    Market Revenue and Forecast, by Type (2017-2030)

9.3.2.    Market Revenue and Forecast, by Product (2017-2030)

9.3.3.    India

9.3.3.1.        Market Revenue and Forecast, by Type (2017-2030)

9.3.3.2.        Market Revenue and Forecast, by Product (2017-2030)

9.3.4.    China

9.3.4.1.        Market Revenue and Forecast, by Type (2017-2030)

9.3.4.2.        Market Revenue and Forecast, by Product (2017-2030)

9.3.5.    Japan

9.3.5.1.        Market Revenue and Forecast, by Type (2017-2030)

9.3.5.2.        Market Revenue and Forecast, by Product (2017-2030)

9.3.6.    Rest of APAC

9.3.6.1.        Market Revenue and Forecast, by Type (2017-2030)

9.3.6.2.        Market Revenue and Forecast, by Product (2017-2030)

9.4.  MEA

9.4.1.    Market Revenue and Forecast, by Type (2017-2030)

9.4.2.    Market Revenue and Forecast, by Product (2017-2030)

9.4.3.    GCC

9.4.3.1.        Market Revenue and Forecast, by Type (2017-2030)

9.4.3.2.        Market Revenue and Forecast, by Product (2017-2030)

9.4.4.    North Africa

9.4.4.1.        Market Revenue and Forecast, by Type (2017-2030)

9.4.4.2.        Market Revenue and Forecast, by Product (2017-2030)

9.4.5.    South Africa

9.4.5.1.        Market Revenue and Forecast, by Type (2017-2030)

9.4.5.2.        Market Revenue and Forecast, by Product (2017-2030)

9.4.6.    Rest of MEA

9.4.6.1.        Market Revenue and Forecast, by Type (2017-2030)

9.4.6.2.        Market Revenue and Forecast, by Product (2017-2030)

9.5.  Latin America

9.5.1.    Market Revenue and Forecast, by Type (2017-2030)

9.5.2.    Market Revenue and Forecast, by Product (2017-2030)

9.5.3.    Brazil

9.5.3.1.        Market Revenue and Forecast, by Type (2017-2030)

9.5.3.2.        Market Revenue and Forecast, by Product (2017-2030)

9.5.4.    Rest of LATAM

9.5.4.1.        Market Revenue and Forecast, by Type (2017-2030)

9.5.4.2.        Market Revenue and Forecast, by Product (2017-2030)

Chapter 10.  Company Profiles

10.1.              Merck Animal Health

10.1.1.  Company Overview

10.1.2.  Type Offerings

10.1.3.  Financial Performance

10.1.4.  Recent Initiatives

10.2.              Ceva

10.2.1.  Company Overview

10.2.2.  Type Offerings

10.2.3.  Financial Performance

10.2.4.  Recent Initiatives

10.3.              Zoetis

10.3.1.  Company Overview

10.3.2.  Type Offerings

10.3.3.  Financial Performance

10.3.4.  Recent Initiatives

10.4.              Boehringer Ingelheim GmbH

10.4.1.  Company Overview

10.4.2.  Type Offerings

10.4.3.  Financial Performance

10.4.4.  Recent Initiatives

10.5.              Elanco

10.5.1.  Company Overview

10.5.2.  Type Offerings

10.5.3.  Financial Performance

10.5.4.  Recent Initiatives

10.6.              Indian Immunologicals Ltd.

10.6.1.  Company Overview

10.6.2.  Type Offerings

10.6.3.  Financial Performance

10.6.4.  Recent Initiatives

10.7.              BiogénesisBagó

10.7.1.  Company Overview

10.7.2.  Type Offerings

10.7.3.  Financial Performance

10.7.4.  Recent Initiatives

10.8.              Phibro Animal Health

10.8.1.  Company Overview

10.8.2.  Type Offerings

10.8.3.  Financial Performance

10.8.4.  Recent Initiatives

10.9.              KM Biologics

10.9.1.  Company Overview

10.9.2.  Type Offerings

10.9.3.  Financial Performance

10.9.4.  Recent Initiatives

10.10.           HIPRA

10.10.1.               Company Overview

10.10.2.               Type Offerings

10.10.3.               Financial Performance

10.10.4.               Recent Initiatives

Chapter 11.  Research Methodology

11.1.              Primary Research

11.2.              Secondary Research

11.3.              Assumptions

Chapter 12.  Appendix

12.1.              About Us

12.2.              Glossary of Terms